XNK Therapeutics will perform a proof of concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center. The proof of concept study is to determine the feasibility to expand and activate NK cells from patients with AML using XNK’s platform. The...
research News
CALGARY, Alberta — XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a research paper titled “Raising serum uric acid with a uricase inhibitor worsens PKD in...
BUFFALO, NY – A new research paper was published in Aging, entitled, “XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis.” X-ray repair cross-complementation group 1 (XRCC1) is a pivotal contributor to base excision repair, and its dysregulation has been implicated in the oncogenicity of...
Rare diseases are not so rare. While a single rare disease may only affect a small proportion of the population, as many as 10% of Americans live with rare diseases, and most of those 30 million people have limited or no treatments and lack access to expert care. Now, Yale...
OAK BROOK, Ill. – According to a new 10-year study, screening for breast cancer with digital breast tomosynthesis (DBT) increases cancer detection rates and significantly reduces the rate of advanced cancers compared to conventional 2D digital mammography. The findings were published today in Radiology, a journal of the Radiological Society...
Los Angeles, California – A new UCLA Health study found Kundalini yoga provided several benefits to cognition and memory for older women at risk of developing Alzheimer’s disease including restoring neural pathways, preventing brain matter decline and reversing aging and inflammation-associated biomarkers – improvements not seen in a group who...
Copenhagen, Denmark – The FDA rejected Zealand Pharma’s glucagon receptor agonist in congenital hyperinsulinism (CHI) after identifying problems at a third-party manufacturing site. The company said it remains confident that it can resubmit in the first half of 2024. Zealand revealed last week that the regulator issued a complete response...
WESTON, Fla. — ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 have published a scientific paper in the peer-reviewed journal, Alzheimer’s...
WESTON, Fla. — ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces selection of contract research organization (“CRO”) George Clinical to manage its Phase 2a clinical trial with Cholesterol Efflux MediatorTM VAR...
– Up to 40% of women with triple negative breast cancer (TNBC) experience metastasis to their brain, which affects physical function, independence, personality, quality of life, and significantly increases mortality rates. – Published data demonstrate that inflammasome activation increases proliferation of TNBC cells in the brain, which was prevented by...